Department of Biochemistry, St. Thomas College, Palai, Kottayam, Kerala, India.
Inorganic and Physical Chemistry, Indian Institute of Science, Bangalore, Karnataka, India.
Asian Pac J Cancer Prev. 2023 Nov 1;24(11):3729-3738. doi: 10.31557/APJCP.2023.24.11.3729.
In the present study, we investigated the immunomodulatory effect of a polyherbal formulation referred to as Imusil (IM) on cyclophosphamide (CP) induced immunosuppression model.
CP induced experimental animal model was used for evaluating the immunomodulatory effect of IM. For the study, animals were divided into four groups. Group I is served as the normal control, group II is treated only with CP, group III is treated with the standard drug, levamisole and group IV is treated with IM. The experimental duration was 30 days. At the end of the study, we had evaluated various parameters such as immune organ index, liver marker enzymes, antioxidants, haematological analysis, Th1/Th2 cytokine balance and humoral immune responses were examined using ELISA kits, T-lymphocyte subsets by flow cytometry, and histopathological analysis of the liver, spleen and thymus by H&E staining.
The results obtained from the study revealed that the treatment of immunosuppressed animals with IM significantly (p<0.05) reversed the immune response in a positive manner. Treatment with IM properly shields the immune organs and triggers the cell-mediated and humoral immune responses accordingly. Thus, no significant changes were observed in the haematological parameters. Moreover, IM supplementation helps to boost up the antioxidant activity, thereby preventing oxidative stress-mediated damage, and also protects the liver from the toxicity induced by CP.
The results suggest that IM has the ability to counteract the immunosuppressive effect of chemotherapeutic drugs by stimulating the immune system, along with its potent antioxidant and hepatoprotective properties.
本研究旨在探讨一种名为 Imusil（IM）的复方草药制剂对环磷酰胺（CP）诱导的免疫抑制模型的免疫调节作用。
采用 CP 诱导的实验动物模型来评价 IM 的免疫调节作用。为此，将动物分为四组。第 I 组作为正常对照组，第 II 组仅用 CP 处理，第 III 组用标准药物左旋咪唑处理，第 IV 组用 IM 处理。实验持续 30 天。在研究结束时，我们评估了各种参数，如免疫器官指数、肝标志物酶、抗氧化剂、血液学分析、Th1/Th2 细胞因子平衡和体液免疫反应，使用 ELISA 试剂盒进行检测，T 淋巴细胞亚群通过流式细胞术进行检测，以及肝、脾和胸腺的组织病理学分析通过 H&E 染色进行。
研究结果表明，用 IM 治疗免疫抑制动物可显著（p<0.05）正向逆转免疫反应。用 IM 治疗可适当保护免疫器官，并相应触发细胞介导和体液免疫反应。因此，血液学参数没有观察到显著变化。此外，IM 补充有助于提高抗氧化活性，从而防止氧化应激介导的损伤，并保护肝脏免受 CP 诱导的毒性。
结果表明，IM 具有通过刺激免疫系统来抵抗化疗药物的免疫抑制作用的能力，同时具有强大的抗氧化和保肝作用。
